Birtamimab Pushes the Needle in AL Amyloidosis
July 26th 2023Findings from an analysis of treatment patterns for patients with systemic amyloid light chain amyloidosis have demonstrated that several unmet needs exist, including timely diagnosis and limited survival outcomes for patients with advanced disease.
Birtamimab Under Investigation in Mayo Stage IV AL Amyloidosis
May 19th 2023Morie A. Gertz, MD, discusses the limitations of the current Mayo Stage IV amyloidosis treatment landscape, the rationale for investigating birtamimab in this population, and the importance of raising awareness for the AFFIRM-AL trial.
Dr Gertz on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis
May 17th 2023Morie A. Gertz, MD, discusses the rationale for the phase 3 AFFIRM-AL trial in patients with amyloid light chain amyloidosis and elaborates on the challenges that may arise when enrolling patients to this trial.
Dr Kastritis on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis
May 9th 2023Efstathios Kastritis, MD, discusses the background of birtamimab and the rationale for investigating the agent in combination with standard-of-care chemotherapy in newly diagnosed patients with Mayo Stage IV amyloid light chain amyloidosis in the phase 3 AFFIRM-AL trial.